Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

Analyst Surprised By Exelixis Q2 Revenue Miss, Delays STELLAR-304 Readout, Halts STELLAR-305 Phase 3 Plans

Lab.Pharma.Pharmeuticals

Exelixis Inc. (NASDAQ:EXEL) on Monday reported its first quarter of 2025 adjusted earnings of 75 cents per share, compared to 85 cents a year ago, beating the consensus of 56 cents.

Click here to find out out what EXEL stock is doing now.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.